Hetero Drugs Ltd. has announced the launch of a biosimilar for Roche’s Avastin® (bevacizumab) in India. Hetero is marketing the drug under the brand name “CizumabTM” as a treatment for metastatic colorectal cancer.
Hetero’s launch is the second release of an Avastin® biosimilar in India– earlier this month, Reliance Life Sciences launched its own bevacizumab product under the brand name “Bevacirel.
